Dupilumab and Lymphoma Risk in AD?
Dupilumab is safe from a lymphoma-risk perspective in atopic dermatitis and other type 2 inflammatory diseases, based on real-world data.
-
By
-
Julia Cipriano, MS, CMPP
-
February 9, 2026
-
Clinical Scorecard: Dupilumab and Lymphoma Risk in AD
At a Glance
| Category | Detail |
|---|
| Condition | Atopic Dermatitis (AD) |
| Key Mechanisms | Dupilumab is an interleukin-4 receptor alpha antibody that modulates type 2 inflammatory responses. |
| Target Population | Patients with moderate-to-severe atopic dermatitis and other type 2 inflammatory diseases. |
| Care Setting | Outpatient and specialty care settings. |
Key Highlights
- Dupilumab does not increase lymphoma risk in patients with AD.
- AD and other type 2 inflammatory diseases are associated with increased lymphoma risk.
- Dupilumab may reduce the risk of non-Hodgkin lymphoma compared to other systemic therapies.
- The study utilized a large-scale retrospective cohort design with propensity-score matching.
- Findings support the safety profile of dupilumab in relation to lymphoma risk.
Guideline-Based Recommendations
Diagnosis
- Evaluate patients for atopic dermatitis and associated lymphoma risk.
Management
- Consider dupilumab as a treatment option for moderate-to-severe AD.
Monitoring & Follow-up
- Monitor patients for signs of lymphoma, especially in those with type 2 inflammatory diseases.
Risks
- Be aware of the inherent lymphoma risk associated with type 2 inflammatory diseases.
Patient & Prescribing Data
Patients with moderate-to-severe atopic dermatitis and other type 2 inflammatory diseases.
Dupilumab treatment is associated with a lower rate of non-Hodgkin lymphoma compared to other systemic therapies.
Clinical Best Practices
- Utilize a comprehensive approach to assess lymphoma risk in patients with AD.
- Incorporate patient history and type 2 inflammatory disease status in treatment decisions.
References
